Key facts
- It has raised $740K; the latest was Seed Round ($590K) in Jul 2025.
- Notable investors include CoInvest Capital, FIRSTPICK, BSV Ventures, Erin Gainer.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for PSY-LINK
- ·The full record, as it builds
Funding rounds
No funding rounds for PSY-LINK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PSY-LINK
Developer of a biotechnology platform designed to create sustainable and scalable psychedelic drug production for mental health treatments. The company's platform offers genetically engineered yeast-based biosynthesis that produces classic and novel psychedelic compounds, enabling pharmaceutical industries to access cost-effective and environmentally friendly psychedelics for research and drug development.
- Sector
- Healthcare
- HQ
- Kaunas, Lithuania
- Founded
- 2020
- Employees
- 3
- Website
- psylink.io/
- Ownership
- Privately Held (backing)
PSY-LINK doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PSY-LINK shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PSY-LINK in its N-PORT filings yet. We sweep new filings monthly.